Alex has extensive experience working in investor relations and capital markets with over 15 years of experience across biotech and biopharma investor relations, healthcare investment banking, equity financing, and corporate communications. During this time, he has advised public and private biotech and biopharma companies through IPO preparation, investor messaging, public company readiness, business development, and strategic transactions.

Alex previously led investor relations at Alpine Immune Sciences and Principia Biopharma, where he helped manage Principia’s IPO process and supported the company’s sale to Sanofi. He has also advised biotech companies as a consultant, including work with Alumis during its IPO process. Earlier in his career, he worked in healthcare investment banking at Robert W. Baird, in Equity Capital Markets at SunTrust Robinson Humphrey (now Truist), and in FP&A at PepsiCo.

At New Street IR, Alex helps biotech companies sharpen their investor narrative, prepare key capital markets milestones, and communicate their science, strategy, and value proposition to Wall Street.